日本引入儿童13价肺炎球菌结合疫苗后成人侵袭性肺炎球菌病的临床特征与血清型分布动态变化(2013-2019年)
该研究基于日本全国成人侵袭性肺炎球菌病(IPD)监测,分析2013-2019年1995例患者。2018-2019年期间与2013-2015年相比,致死性结局风险独立降低。引入儿童PCV13后3年内,15-64岁和≥65岁人群中PCV13-nonPCV7血清型比例显著下降;≥65岁人群非疫苗血清型比例显著上升,但15-64岁人群无显著变化。
要点
- 2018-2019年期间与2013-2015年相比,致死性结局风险独立降低。
- 引入儿童PCV13后3年内,15-64岁和≥65岁人群PCV13-nonPCV7血清型比例显著下降。
- ≥65岁人群非疫苗血清型比例显著上升,15-64岁人群无显著变化。
核心结论
- 血清型分布数据支持儿童PCV13使用对成人产生间接效应,并为日本老年人新开发PCV的IPD保护效果估算提供依据。
研究设计与样本
- 基于日本全国成人侵袭性肺炎球菌病监测,2013-2019年共分析1995例患者,按时间段分为早期(2013-2015年)、中期(2016-2017年)和晚期(2018-2019年)。
主要发现
- 2018-2019年期间与2013-2015年期间相比,致死性结局风险独立降低。
- 引入儿童PCV13后3年内,15-64岁和≥65岁人群中PCV13-nonPCV7血清型比例显著下降。
- ≥65岁人群非疫苗血清型比例显著上升,但15-64岁人群无显著变化。
- 15-64岁和≥65岁成人中PPSV23-nonPCV13血清型比例均无显著变化。
- 晚期≥65岁成人IPD患者中,PCV15、PCV20和PCV24覆盖血清型比例分别为38%、56%和58%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nationwide population-based surveillance for invasive pneumococcal disease (IPD) is being conducted in few Asian countries. We aimed to evaluate the clinical characteristics and serotype distribution among Japanese adult patients with IPD after introduction of the pediatric 13-valent pneumococcal conjugate vaccine (PCV13) in 2013. IPD surveillance was conducted among adults between 2013 and 2019, and 1,995 patients were analyzed by time period (early, 2013-2015; middle, 2016-2017; late, 2018-2019). We found that the period of 2018-2019 was independently associated with a lower risk of fatal outcome, compared with the period of 2013-2015. The proportion of those with serotype PCV13-nonPCV7 decreased significantly in patients aged 15-64 years and in those aged ≥ 65 years within 3 years after the introduction of pediatric PCV13. By contrast, the proportion of those with nonvaccine serotype increased significantly in those aged ≥ 65 years, but not in those aged 15-64 years. No significant change was found in the proportion of 23-valent polysaccharide pneumococcal vaccine (PPSV23)-nonPCV13 in both of adults aged 15-64 years and ≥ 65 years. The proportions of PCV15-, PCV20- and PCV24-covered serotypes were 38%, 56% and 58% in adult patients with IPD aged ≥ 65 years during the late period. Our data on the serotype distribution support an indirect effect from pediatric PCV13 use among adults, and afford a basis for estimates of protection against IPD by vaccination with newly developed PCVs in older adults in Japan.
引用
- Tamura K, Chang B, Shimbashi R, et al. Dynamic changes in clinical characteristics and serotype distribution of invasive pneumococcal disease among adults in Japan after introduction of the pediatric 13-valent pneumococcal conjugate vaccine in 2013-2019. Vaccine. 2022. PMID: 35489986. doi:10.1016/j.vaccine.2022.04.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。